Michael H. Tirgan, M.D., the founder of Phase 1 Oncology, is a board-certified medical oncologist with over a decade of experience in oncology drug development, with special expertise in early stages of the drug development process.
Following the completion of his fellowship training in hematology/oncology in 1990, Dr. Tirgan entered clinical practice. His exposure to pharmaceutical research and oncology drug development started in 2007 when he joined Boehringer Ingelheim Pharmaceuticals and ever since he has held various positions within the industry. Most recently, he has provided oncology drug development consulting services to various pharmaceutical companies.
Since 2008, Dr. Tirgan has focused his medical practice on the treatment of keloid disorder and has treated over 1,400 keloid patients, adults, and children, with all types of keloids. In 2011, Dr. Tirgan established the Keloid Research Foundation, a non-profit medical research, and educational organization, with the mission of fostering scientific research in keloid disorder and promoting education, advocacy, and service to those who suffer from this disorder. He is the main organizer of the Keloid Symposium and an advocate of international collaboration among all clinicians and scientists who have an interest in clinical or laboratory research of keloid disorder. He has been an invited speaker to several international meetings and has presented his clinical research and outcome results as well as treatment strategy for managing keloid patients. In November 2016, Dr. Tirgan established the International Journal of Keloid Research, the only journal that is solely focused on clinical and laboratory research of keloid disorder.
Dr. Tirgan is an attending physician at Mount Sinai St. Luke’s and Roosevelt Hospitals, and an associate attending physician at The Rockefeller University Hospital in New York. He is also a clinical instructor at the Icahn School of Medicine at Mount Sinai.